spacer
home > epc > autumn 2002 > global acceptability of clinical data - fact or fiction?
PUBLICATIONS
European Pharmaceutical Contractor

Global Acceptability of Clinical Data - Fact or Fiction?

One of the challenges of running clinical trials is obtaining adequate representation from all the groups in society that may receive a potential new medicine. As a result, regulators may be placed in a difficult position regarding the approval of new drugs where the majority of the dossier comprises of foreign clinical data.

The pharmaceutical industry is also in a difficult position as trials grow in size and become more expensive to run. With companies devoting up to 40 per cent of their R&D expenditure to clinical evaluation, companies cannot afford to run trials that will account for every foreign patient group that might receive a potential drug.

This has led to worries that patients in some countries will not be able to gain access to certain drugs because regulatory authorities will be reluctant to approve them. Japan is often cited as an example in such cases. For example, of the 149 drugs approved in the US between 1992 and 1996, 51 per cent were not available to patients in Japan by 2000 (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Carly Anderson and Faiz Kermani of CMR International

Carly Anderson joined CMR International in April 1999. She has been involved in a number of projects including those in the areas of regulations, pharmaceutical investment and output and marketed medicines.

She graduated from King's College, London with a molecular biology degree and a special interest in genetics.

Dr Faiz Kermani joined CMR International as a Research Associate in October 1999 from Imperial College, London, where he was carrying out postdoctoral research in immunology.

Previously, he obtained a PhD in Immunopharmacology from St. Thomas' Hospital, London, and a First Class Honours Degree in Pharmacology with Toxicology from King's College, London. Faiz has also worked as a Research Analyst for Danish health care company, Informedica a/s, writing on European and North American health care issues.


spacer
Carly Anderson
spacer
spacer
spacer
Dr Faiz Kermani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

The Avoca Group

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement